News and Trends 8 Jan 2018
Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis
TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […]